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AbstrAct
Introduction Anderson-Fabry disease (AFD) is an 
X-linked lysosomal storage disorder caused by mutations 
of GLA gene leading to reduced α-galactosidase 
activity and resulting in a progressive accumulation of 
globotriaosylceramide (Gb3) and its deacylated derivative, 
globotriaosyl-sphingosine (Lyso-Gb3). Plasma Lyso-
Gb3 levels serve as a disease severity and treatment 
monitoring marker during enzyme replacement therapy 
(ERT).
Methods Adult patients with AFD who had yearly 
pulmonary function tests between 1999 and 2015 were 
eligible for this observational study. Primary outcome 
measures were the change in z-score of forced expiratory 
volume in the first second (FEV1) and FEV1/FVC over time. 
Plasma Lyso-Gb3 levels and the age of ERT initiation 
were investigated for their association with lung function 
decline.
results Fifty-three patients (42% male, median (range) 
age at diagnosis of AFD 34 (6–61) years in men, 34 (13–
67) in women) were included. The greatest decrease of 
FEV1/FVC z-scores was observed in Classic men (−0.048 
per year, 95% CI −0.081 to –0.014), compared with the 
Later-Onset men (+0.013,95% CI −0.055 to 0.082), 
Classic women (−0.008, 95% CI −0.035 to +0.020) and 
Later-Onset women (−0.013, 95% CI −0.084 to +0.058). 
Cigarette smoking (P=0.022) and late ERT initiation 
(P=0.041) were independently associated with faster 
FEV1 decline. FEV1/FVC z-score decrease was significantly 
reduced after initiation of ERT initiation (−0.045 compared 
with −0.015, P=0.014). Furthermore, there was a trend 
towards a relevant influence of Lyso-Gb3 (P=0.098) on 
airflow limitation with age.
conclusion Early ERT initiation seems to preserve 
pulmonary function. Plasma Lyso-Gb3 is maybe a useful 
predictor for airflow limitation. Classic men need a closer 
monitoring of the lung function.
IntroductIon
Anderson-Fabry disease (AFD) is an X-linked 
lysosomal storage disorder caused by muta-
tions of GLA gene leading to reduced or 
absent α-galactosidase A (α-gal A) enzyme 
activity resulting in progressive accumula-
tion of neutral glycosphingolipids, such as 
globotriaosylceramide (Gb3), and its deac-
ylated soluble derivative globotriaosylsphin-
gosine (Lyso-Gb3) in the plasma and in tissue 
lysosomes.1 Eventually, ruptured lysosomes 
deliberate their content in the extracellular 
matrix triggering inflammation and subse-
quent fibrosis.2 Since the vascular endothe-
lium is highly sensitive to this kind of damage, 
kidneys, cardiovascular system, nervous system 
and skin are mainly affected by the disease.3 
In addition, a similar mechanism is suggested 
concerning the smooth muscle cells of upper 
and lower airways, which may further lead to 
obstructive sleep apnoea or bronchial/bron-
chiolar obstruction, respectively.4 5 
Classic and Later-Onset phenotypes are 
known in AFD. Men with the Classic pheno-
type have mutations that cause an absent or 
very low (<1%) α-gal A activity and result in 
an early onset of acroparesthesias, angio-
keratoma, cornea verticillata, hypohidrosis, 
gastrointestinal cramping and diarrhoea.6–8 
With advancing age, progressive Gb3 accu-
mulations culminate in hypertrophic cardio-
myopathy, renal failure, cerebrovascular 
disease and obstructive pulmonary disease. 
Key messages
 ► Does early initiation of enzyme replacement 
therapy (ERT) and accumulation of globotriaosyl-
sphingosine (Lyso-Gb3) have an effect on lung 
function decline in patients with Anderson-Fabry 
disease (AFD)?
 ► Early initiation of ERT and smoking cessation seem 
to have a beneficial effect on lung function decline 
in AFD. Plasma Lyso-Gb3 may be used as predictor 
for disease severity and accelerated lung function 
impairment.
 ► Pulmonologists should be aware of lung 
involvement in AFD since early diagnosis and 
treatment are potentially crucial.
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In contrast, men with the Later-Onset phenotype have 
mutations that cause a significant (>1%) residual α-gal A 
activity and result in cardiac, renal and cerebrovascular 
disease in the fourth to sixth decades of life without early 
clinical manifestations.8–11
Risk factors for both phenotypes are less clear and are 
difficult to define due to the low disease prevalence, hetero-
geneous disease manifestations and, in women, additionally 
due to a random x-chromosomal deactivation.12 13 More-
over, there is considerable uncertainty with regard to initia-
tion of enzyme replacement therapy (ERT),14 which makes 
data on respiratory involvement difficult to interpret. Thus, 
more studies are needed to definitively underpin the associ-
ation between AFD and different organ, particularly respi-
ratory, involvement. Particularly, the effect of biomarkers, 
such as Gb3 and Lyso-Gb3, and the optimal timing of ERT 
initiation on respiratory involvement has not been investi-
gated to date.
Residual α-gal A activity was demonstrated inversely 
proportional to plasma Lyso-Gb3 levels.15 Yet, Lyos-Gb3 
is markedly increased in the plasma of classical Fabry 
patients with a higher sensitivity compared with Gb3 for 
the diagnosis of AFD, also in heterozygous women.16–18 
Moreover, beside its use as diagnostic tool, Lyso-Gb3 
seems to be a reliable therapeutic marker17 19 20 or a 
biomarker to predict clinical severity of the disease.21
The aim of the present study was to investigate whether 
Lyso-Gb3 might be a predictive biomarker for respiratory 
involvement of AFD as assessed by its association with 
pulmonary function decline alongside with other vari-
ables. Furthermore, we aimed to investigate the effect of 
ERT initiation on lung function decline with age.
MAterIAls And Methods
Patients
All patients in the AFD cohort at the University Hospital 
Zurich, which has been established in 2001 when ERT 
was in development, usually have at least one scheduled 
outpatient consultation in our centre per year. These 
consultations comprise an extensive clinical work-up 
of all possible manifestations related to AFD, such as 
cardiovascular system, kidneys, nervous system, eyes and 
lung. For purposes of the latter, there are yearly pulmo-
nary function tests (PFTs). Based on the results of the 
aforementioned examinations, indications for ERT are 
discussed at quarterly conferences with participation 
of all involved disciplines. ERT was prescribed at the 
licensed dose of either 0.2 mg/kg body weight of recom-
binant agalsidase-α (Replagal) or 1 mg/kg body weight 
agalsidase-β (Fabrazyme) and given intravenously every 
14 days. ERT was indicated in all men. In women, ERT was 
indicated if they had proteinuria of more than 300 mg per 
day, Fabry-typical kidney biopsy findings, signs of Fabry 
cardiomyopathy such as left ventricular hypertrophy or 
arrhythmia, stroke or transient ischaemic attack, acropar-
esthesias despite conventional analgesic therapy and/
or gastrointestinal symptoms. All adult patients of this 
cohort who were treated and followed up at our centre 
from 1999 until 2015 were eligible for this retrospective 
observational study. Patients with at least two consecutive 
PFTs and known plasma Lyso-Gb3 value were included 
in the study. All patients had a Lyso-Gb3 measurement 
between October 2013 and December 2016 and had no 
ERT initiation or switch within at least 2 years prior to the 
measurement, so that the individual LysoGb3 levels were 
in the stable phase, as it has been shown previously.17
The study was approved by the Ethics committee of the 
canton of Zurich, Switzerland (KEK-ZH 2012–0115), and is 
registered at  ClinicalTrials. gov (Identifier: NCT01632111).
Pulmonary function testing
Yearly PFTs (spirometry) were performed according to 
performance standards based on the statements from the 
American Thoracic Society and the European Respiratory 
Society (ERS)22 at the Department of Pulmonology. The 
patients were asked to withhold from cigarette smoking 
at least 4 hours before PFT. Lung volumes were measured 
with a commercial ZAN300 system (nSpire Health GmbH, 
Oberthulba, Germany). Since z-scores are not biased 
by age and misdiagnosis occurs when fixed cut-offs are 
Figure 1 Patient flow chart. PFT, pulmonary function test.
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used,23 the lower limit of normal was defined by the fifth 
centile, corresponding to −1.64 z-scores according to the 
ERS Global Lung Function Initiative.24 Thus, as criterion 
to define airflow limitation, we used the ratio between the 
forced expiratory volume in the first second (FEV1) and the 
forced (expiratory) vital capacity (FVC) with a z-score cut-off 
of equal or below −1.64 rather than the fixed cut-off value 
of FEV1/FVC <70%, as recommended by others.
23 25 Deter-
mination of individual z-scores was achieved with GLI-2012 
Desktop Software for Individual Calculations.26
outcome measures
Primary outcome measures were the change in z-scores of 
FEV1 and FEV1/FVC over time. The secondary goal was to 
investigate factors, which may affect change in FEV1 and 
FEV1/FVC over time. For this purpose, age, sex, cigarette 
smoking, AFD phenotype (Classic vs. Later-Onset), residual 
α-gal activity, age at ERT initiation, Mainz Severity Score 
Index (MSSI) and Lyso-Gb3 were assessed. Cigarette 
smoking was considered positive if greater than one pack-
year. MSSI is a clinical scoring system to determine the 
severity of Fabry disease, considering general, neurological, 
cardiovascular and renal abnormalities27. Cardiac involve-
ment was defined positive if at least one cardiac MSSI vari-
able was fulfilled. Measurement of plasma Lyso-Gb3 was 
performed using nano-liquid chromatography–tandem 
mass spectrometry system, which was validated recently.8 18
Phenotyping
The phenotype was determined as Classic or Later-Onset 
based on the specific GLA mutation as reported previ-
ously.8 18 28 For novel missense mutations, the phenotype 
Table 1 Baseline patient characteristics and treatment
Baseline characteristics Men, n=22 Women, n=31 P value
Classic phenotype 20 (90.9%) 27 (90.0%) 0.45
Cardiac involvement 14 (63.6) 11 (35.5) 0.05
Age at baseline (diagnosis of AFD), years 34 (6–61) 30 (13–67) 0.99
Age at ERT initiation, years 39 (14–62) 43 (16–68) 0.71
Time from baseline to ERT initiation, months 12 (0–384) 12 (0–432) 0.72
Patients on ERT 21 (95.5) 19 (61.3) 0.007
Patients on bronchodilators 2 (9.1) 1 (3.2) 0.56
Current or former cigarette smoking 7 (31.8%) 9 (36.0%) 1.00
MSSI, points 16 (0–40) 8 (0–33) 0.01
Residual α-gal activity, % 5.5 (1.8–52.8) 41.8 (2.2–163.0) <0.001
Lyso-Gb3, ng/mL 40.1 (2.0–115.0) 8.6 (0.8–23.1) <0.001
FEV1, L 3.0 (1.8–4.1) 2.4 (1.8–3.3) 0.002
FEV1, % predicted 86.0 (54.0–116.0) 87.0 (66.0–110.0) 0.55
FEV1, z-score −2.3 (−4.4–0.7) −1.6 (−3.1–0.2) 0.31
FEV1, z-score ≤−1.64 13 (56.5%) 13 (43.3%) 0.41
FVC, L 4.2 (2.1–5.4) 3.0 (2.3–4.2) <0.001
FVC, % predicted 91.0 (76.0–125.0) 95.0 (72.0–118.0) 0.86
FVC, z-score −1.6 (−3.6–1.1) −1.6 (−2.7–0.7) 0.81
FVC z-score ≤−1.64 6 (27.3) 9 (29.0) 0.37
FEV1/FVC, % 73 (47–88) 78 (70–93) 0.009
FEV1/FVC, z-score −0.9 (−5.3–1.4) −0.6 (−2.6–1.5) 0.12
FEV1/FVC, z-score ≤−1.64 5 (21.7%) 3 (10.0%) 0.27
FEF25%–27%, L 2.2 (0.7–5.4) 1.9 (1.0–5.2) 0.36
FEF25%–27%, % predicted 54.0 (20.0–119.0) 55.5 (26.0–107.0) 0.67
FEF25%–27%, z-score −1.4 (−3.5–1.4) −1.2 (−3.6–2.6) 0.48
FEF25%–27%, z-score ≤−1.64 9 (40.9) 8 (25.8) 0.03
DLCO, % predicted 82.0 (63.0–108.0) 88. (61.0–115.0) 0.44
Values are presented as n (%) for categorical variables (P values from Fisher’s exact test) or median (range) for continuous variables (P values 
from Mann-Whitney U test).
AFD, Anderson-Fabry disease; DLCO, CO diffusion capacity of the lung; ERT, enzyme replacement therapy; FEF25%–27%, forced expiratory 
flow between 25% and 75% of FVC; FEV1, forced expiratory volume in the first second; FVC, forced (expiratory) vital capacity; MSSI, Mainz 
Severity Score Index; α-gal, α-galactosidase A activity.
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was based on clinical signs and symptoms in affected men 
and by in vitro expression assays.29 30
lyso-Gb3 measurement
For serum Lyso-Gb3 levels, blood samples were centri-
fuged and serum was immediately frozen at −80°C for 
a later batch analysis. The samples were measured by 
high-sensitivity electrospray ionisation liquid chromatog-
raphy–tandem mass spectrometry.31 A seven-point serum 
calibrator and an internal standard for Lyso-Gb3 quantifi-
cation (covering the analytic range from 0 to 120 ng/mL; 
lower limit of quantification: 0.3 ng/mL), and three level 
controls (3, 30 and 100 ng/mL) for quality control were 
used (ARCHIMED Life Science GmbH, Vienna, Austria; 
www. archimedlife. com). The lower limit of quantification 
was determined according to EP guideline 17A2 using 
Lyso-Gb3 calibrators 0, 0.5 and 1.0 ng/mL. The labora-
tory members were blinded to patient’s ID numbers, sex 
and all clinical and biochemical information and were 
not involved in the collection of samples, interpretation 
of data or the decision to submit this article for publica-
tion.
statistical analysis
Data were summarised as n (%) or median (range). Vari-
ables have been included in regression models either as 
nominal variables or, in case of continuous data, divided 
into three equally sized categories. Slopes have been 
estimated using linear mixed models, considering age 
as the time variable, and including a random intercept 
and slope for each subject. For models comparing slopes 
by levels of a categorical variable x, the P value of the 
interaction term was used to compare the slopes, and 
mean estimated slopes were computed from the sum of 
the coefficients for age and the interactions terms with 
each level of x. Multivariable models have been further 
adjusted by inclusion of other variables that had a P value 
of equal or less than 0.10 in the univariable analysis. 
Two-sided P values were considered statistically signifi-
cant if they were less than 0.05.
Statistical analysis was performed using R (R Core 
Team, 2013) (R V.3.4.0 (2017-04-21)), with linear mixed 
models estimated using the lme432 package (P values 
computed using the lmerTest package33). Calculation of 
slopes from the coefficients for the fixed effects has been 
performed using the multcomp34 package.
results
From 101 eligible patients, 53 patients (42% male) 
performing totally 252 PFTs were included in the study 
(figure 1). Baseline characteristics are shown in table 1 
and the detailed demographic and biochemical informa-
tion in online supplementary table 1. At baseline (diag-
nosis of AFD), the median age in men was 34 (range 
6–61) and in women 34 (13–67) years.
In total, 40 patients were under ERT. Thirty patients 
received agalsidase-α and four agalsidase-β only 
throughout the observational period. Further six patients 
were switched at least once between the both ERT prepa-
rations. Thirteen patients were not on ERT: 1 man due to 
compliance reasons and 12 women due to lack of indica-
tion or compliance reasons.
changes in FeV1 and FeV1/FVc over time
Median (IQR) spirometric follow-up time was 7.7 (3.7–
10.1) years. When considering z-scores, 8 of 53 patients 
(15%) had airflow limitation (defined as FEV1/FVC 
(z)≤−1.64) at baseline and a total of 27 patients (51%) 
developed airflow limitation over time. For all patients, 
mean absolute FEV1 decline was −29.6 mL per year of age 
(95% CI −34.5 to –21.3 mL), and FEV1 z-score decreased 
annually by −0.01 (95% CI −0.03 to 0.06). FVC decline was 
Figure 2 Change in FEV1/FVC (z-scores) over time. All values on y-axis are presented as z-scores from FEV1/FVC for Classic 
(A) and Later-Onset (B) patients, respectively, whereas age (in years) is represented by x-axis. Median (IQR) spirometric 
follow-up time was 7.7 (3.7–10.1) years.
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−21.1 mL per year of age (95% CI −34.4 to –7.6 mL), and 
FVC z-score decline decreased annually by −0.007 (95% 
CI 0.02 to 0.01). Compared with this, FEV1/FVC z-score 
decreased −0.02 (95% CI −0.05 to −0.005) per year.
The slopes over time of FEV1/FVC in z-scores for men 
and women according to the phenotype are illustrated 
in figure 2. The greatest decrease of FEV1/FVC z-scores 
was observed in Classic men (−0.048 per year, 95% CI 
−0.081 to –0.014) compared with the Later-Onset men 
(+0.013, 95% CI −0.055 to 0.082), Classic women (−0.008, 
95% CI −0.035 to +0.020) and Later-Onset women 
(−0.013, 95% CI −0.084 to +0.058).
Factors affecting change in FeV1 and FeV1/FVc over time
Univariate associations of slope of the two z-score outcomes 
with various factors are shown in table 2. Statistically signif-
icantly different slopes of FEV1 were seen by sex (P=0.048), 
smoking status (P=0.037), cardiac involvement by Fabry 
disease (P=0.033) and age at ERT initiation (P=0.029). Thus, 
male sex, active smoking or history of cigarette smoking, 
cardiac involvement and increased patient age at ERT initia-
tion were associated with faster FEV1 decline compared with 
women, non-smokers, no cardiac involvement and early 
therapy start. Airflow limitation was significantly influenced 
by Lyso-Gb3 (P=0.022) and MSSI (P=0.007) with higher 
values associated with faster decline of FEV1/FVC.
Table 3 shows the results from the multivariable models, 
adjusting for other factors (sex, smoking, Lyso-Gb3, MSSI 
and age at ERT initiation). The only significant interactions 
with age after adjustment were history of cigarette smoking 
(P=0.022) and age at ERT initiation (P=0.041) with FEV1 
(figure 3). Thus, current or former smokers and those with 
delayed ERT initiation had significantly faster FEV1 decline. 
There was no significant association of the investigated vari-
ables with airflow limitation over time. However, there was a 
considerable trend towards a clinically relevant influence of 
Lyso-Gb3 (P=0.098) on airflow limitation with age (figure 4). 
Considering a model where the change in pulmonary func-
tion parameters over time varying by ERT status, there was 
a statistical significant interaction for the FEV1/FVC z-score 
with an improved slope (−0.045 compared with −0.015, 
P=0.014) after initiation of ERT (table 4).
dIscussIon
There is increasing evidence of a functionally rele-
vant pulmonary involvement of AFD, which is clinically 
Table 2 Univariable analysis of estimated slopes by categorised covariates
Variable Levels FEV1 (z) P value FEV1/FVC (z) P value
Phenotype Classic −0.011 (−0.031, 0.008) −0.027 (−0.048, –0.005)
Later-Onset −0.027 (−0.082, 0.027) 0.55 −0.001 (−0.057, 0.055) 0.37
Sex Female 0.005 (−0.020, 0.030) −0.007 (−0.034, 0.021)
Male −0.030 (−0.056, –0.004) 0.048 −0.034 (−0.065, –0.003) 0.17
Smoking Never smoker 0.002 (−0.022, 0.025) −0.022 (−0.051, 0.007)
Smoker −0.039 (−0.070, –0.008) 0.037 −0.023 (−0.060, 0.014) 0.95
Cardiac involvement Yes −0.043 (−0.073, –0.013) −0.025 (−0.061, 0.011)
No 0.001 (−0.030, 0.031) 0.033 −0.034 (−0.070, 0.002) 0.72
Lyso-Gb3, ng/mL <8.6 0.012 (−0.030, 0.053) 0.59 −0.012 (−0.050, 0.026) 0.5
8.6–21.2 −0.001 (−0.034, 0.032) 0.004 (−0.029, 0.037)
≥21.3 −0.032 (−0.064, 0.000) 0.14 −0.048 (−0.082, –0.013) 0.022
α-Gal activity, % <9 −0.040 (−0.084, 0.004) 0.096 −0.034 (−0.082, 0.014) 0.36
Sep-40 0.013 (−0.036, 0.062) −0.003 (−0.052, 0.047)
≥41 0.007 (−0.045, 0.059) 0.85 0.010 (−0.041, 0.060) 0.75
Age at diagnosis, years <25 −0.007 (−0.054, 0.040) 0.07 −0.091 (−0.150, –0.033) 0.13
25–41 −0.056 (−0.096, 0.016) −0.053 (−0.101, –0.004)
≥42 −0.039 (−0.081, 0.002) 0.5 −0.033 (−0.081, 0.016) 0.5
MSSI, points <6 −0.009 (−0.053, 0.035) 0.67 −0.024 (−0.069, 0.021) 0.15
6–15.6 0.002 (−0.035, 0.040) 0.016 (−0.023, 0.055)
≥15.7 −0.018 (−0.051, 0.014) 0.35 −0.050 (−0.084, –0.016) 0.007
Age at ERT initiation, 
years
<35 0.004 (−0.046, 0.054) 0.029 −0.061 (−0.128, 0.005) 0.95
35–45 −0.059 (−0.098, –0.019) −0.064 (−0.117, –0.011)
≥46 −0.037 (−0.079, 0.006) 0.38 −0.007 (−0.063, 0.049) 0.093
Values are estimated slopes of z-values (95% CI) and P values, respectively. For covariates with three categories, the ranges for each 
category are lowest, mid (highest minus lowest), highest. Median (IQR) spirometric follow-up time was 7.7 (3.7, 10.1) years. 
α-Gal, α-galactosidase A enzyme; ERT, enzyme replacement therapy; MSSI, Mainz Severity Score Index.
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apparent as airflow limitation early in lifetime of these 
patients compared with non-Fabry diseased popu-
lations.5 35–37 The pathological mechanism of this 
disorder is most likely due to lysosomal accumulation 
of neutral glycosphingolipids in bronchial mucosa and 
smooth-muscle cells that result in small and medium 
airway narrowing.35 38–44 However, due to limited sample 
sizes of the available studies on this orphan disease and 
due to heterogeneous phenotypes of AFD and uncer-
tainty with regard to adequate timing of ERT initiation, 
Table 3 Multivariable analysis of estimated slopes by categorised covariates
Variable Levels FEV1 (z) P value FEV1/FVC (z) P value
Sex Female −0.025 (−0.062, 0.013) −0.044 (−0.089, 0.001)
Male −0.052 (−0.082, –0.022) 0.19 −0.070 (−0.106, –0.028) 0.26
Smoking Never smoker −0.025 (−0.055, 0.005) −0.059 (−0.099, –0.020)
Smoker −0.073 (−0.109, –0.037) 0.022 −0.063 (−0107, –0.019) 0.86
Lyso-Gb3, nmol/L <8.6 −0.020 (−0.078, 0.038) 0.65 −0.042 (−0.101, 0.017) 0.54
8.6–21.2 −0.034 (−0.079, 0.011) −0.027 (−0.077, 0.024)
≥21.3 −0.049 (−0.085, –0.011) 0.52 −0.073 (−0.116, –0.030) 0.098
MSSI, points <6 −0.044 (−0.096, 0.008) 0.79 −0.067 (−0.126, –0.010) 0.15
6–15.6 −0.037 (−0.083, 0.008) −0.021 (−0.075, 0.032)
≥15.7 −0.042 (−0.079, –0.006) 0.73 −0.069 (−0.113, –0.026) 0.053
Age at ERT initiation, 
years
<35 −0.013 (−0.063, 0.037) 0.041 −0.091 (−0.154, 0.028) 0.17
35–45 −0.056 (−0.107, –0.005) −0.037 (−0.101, –0.028)
≥46 −0.031 (−0.078, 0.016) 0.42 −0.004 (−0.054, 0.062) 0.28
Values are estimated slopes (95% CI) and P values, respectively. For covariates with three categories, the ranges for each category are 
lowest, mid (highest minus lowest), highest. Median (IQR) spirometric follow-up time was 7.7 (3.7, 10.1) years.
ERT, enzyme replacement therapy; MSSI, Mainz Severity Score Index.
Figure 3 Slope of FEV1 by age at enzyme replacement 
therapy (ERT) initiation FEV1 z-score slope (y-axis) by age 
categorised in three groups (red, ERT initiation <35 years; 
green, ERT initiation between 35 and 45 years; blue, ERT 
initiation above 46 years). ERT initiation <35 years resulted 
in improvement of FEV1 over time compared with later 
initiation. Median (IQR) spirometric follow-up time was 7.7 
(3.7, 10.1) years.
Figure 4 Slope of FEV1/FVC by Lyso-Gb3 category FEV1/
FVC z-score (y-axis) by age (x-axis) categorised by three 
categories according to Lyso-Gb3 levels (red, lowest Lyso-
Gb3 level of 8.6 ng/mL; green, mid level of Lyso-Gb3; blue, 
highest Lyso-Gb3 level of 21.3 ng/mL). Patients with highest 
Lyso-Gb3 levels had faster FEV1/FVC z-score decline 
compared with those with lower levels. Median (IQR) 
spirometric follow-up time was 7.7 (3.7, 10.1) years.
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patients at increased risk of pulmonary involvement are 
difficult to define.12 Notably, neither MSSI nor residual 
α-gal activity was associated with FEV1 decline or the 
appearance of airflow limitation in the latter study.
In the present considerably large single-centre cohort 
study on patients of both sexes with AFD, we have 
addressed this gap by investigating plasma Lyso-Gb3 and 
age at ERT initiation in addition to conventional factors 
that have been described in a recent publication by our 
group.12 Plasma Lyso-Gb3 has been demonstrated to be 
a reliable therapeutic marker17 20 45 as well as biomarker 
to predict clinical severity of AFD.21 Thus, we hypothe-
sised that plasma Lyso-Gb3 in patients with AFD might 
correlate with lung function decline, particularly the 
appearance of airflow limitation.
We found that increased plasma Lyso-Gb3 levels show 
an independent trend towards a clinically relevant risk 
of airflow limitation with age. Thus, plasma Lyso-Gb3 is 
likely to be a useful predictor of pulmonary involvement 
in terms of early airflow limitation and might help for 
risk stratification and treatment decisions. Notably, there 
was no other factor associated with airflow limitation over 
time, yet Lyso-Gb3 might have become significant with 
a higher number of included subjects. Noteworthy, the 
suggested relationship between Lyso-Gb3 and airflow 
limitation underlines the existence of pulmonary involve-
ment by AFD.
Importantly, pulmonary involvement seems to be more 
prominent in Classic than in Later-Onset men and the 
women of both phenotypes. This finding suggests that 
the residual α-gal A activity in women and Later-Onset 
phenotype individuals is sufficient to clear the bronchial 
mucosa and smooth-muscle cells from the Gb3 deposi-
tions, this in analogy to the vascular endothelial cells.1
Attempts to predict the lung phenotype based on the 
type or location of the GLA mutation have already been 
undertaken by the group of Brown et al.35 In this study, 
three patients with frameshift mutations and two with 
the missense mutation D264V, which markedly alters 
the enzymatic α-gal A structure and function, exhibited 
airway obstruction, consistent with the absence of enzy-
matic activity. In contrast, the patients with other, less 
severe missense mutations did not. The authors stated 
that drawing conclusions may be somewhat premature 
because their studies were limited by the small number 
of patients. Our much larger study confirms this previous 
assumption and our results suggest that closer systematic 
monitoring of Classic men for pulmonary disease might 
be helpful in diagnosing and early treatment of Fabry 
pneumopathy.
Concerning FEV1 slopes, we found that cigarette 
smoking and later ERT initiation were associated with 
faster FEV1 decline. The latter finding brings new light 
into an area of uncertainty. There are limited data on the 
effect of ERT on pulmonary involvement of AFD,40 44 46 47 
and the optimal time for initiation of ERT is unknown.35 
Several case reports and small case series stated that 
ERT has beneficial effects on PFT by stabilising or even 
increasing FVC and/or FEV1.
40 44 46 Our data suggest 
that an earlier ERT initiation probably helps to stabilise 
FEV1 decline and preserve pulmonary function. Simi-
larly, Arends et al found in their retrospective cohort 
that ERT initiation before the age of 25 years resulted in 
lower Lyso-Gb3 levels after 1 year compared with those 
with a later treatment start.20 Thus, early ERT initiation 
seems to result in better biochemical response and, 
subsequently, slower FEV1 decline. Furthermore, we were 
able to show a significantly improved annual decrease of 
FEV1/FVC z-score after initiation of ERT compared with 
before the onset of treatment, which is a unique finding 
in the literature.
The possible association between cigarette smoking 
and FEV1 decline in patients with AFD is not new and 
confirms the findings of others.35 48 However, a very 
recent study by our group found no significant associa-
tion between cigarette smoking and FEV1 decline.
12
Since this is the first study to show a probable associ-
ation between plasma Lyso-Gb3 and airflow limitation, 
and an independent association between age at ERT 
initiation and FEV1 decline, respectively, these findings 
Table 4 Annual pulmonary function changes before and after initiation of enzyme replacement therapy
Before initiation of ERT After initiation of ERT P value
FEV1, mL −32.4 (−43.5, –21.4) −26.3 (39.7, –13.0) 0.12
FEV1, z-score −0.010 (−0.029, 0.009) −0.010 (−0.036, 0.015) 0.99
FVC, mL −14.7 (−29.3, –10.0) −14.3 (−30.8, 2.1) 0.11
FVC, z-scores 0.157 (−0.155, 0.470) 0.077 (−0.182, 0.337) 0.42
FEV1/FVC, z-score −0.045 (−0.075, –0.014) −0.015 (−0.036, 0.006) 0.014
FEF25%–75%, mL −45.1 (−64.7, –25.5) −43.3 (−56.5, –30.1) 0.81
FEF25%–75%, z-score −0.004 (−0.030, 0.022) 0.002 (−0.014, 0.018) 0.56
DLCO, % predicted 0.07 (−0.32, 0.47) −0.09 (−0.36, 0.17) 0.34
Values are estimated slopes (95% CI) of annual pulmonary function change, whereas median (IQR) spirometric follow-up time was 7.7 (3.7, 
10.1) years.
DLCO, CO diffusion capacity of the lung; ERT, enzyme replacement therapy; FEF25%–75%, forced expiratory flow between 25% and 75% 
of FVC; FEV1, forced expiratory volume in the first second; FVC, forced (expiratory) vital capacity.
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must be confirmed in a larger cohort. However, our 
study has included a considerably large sample size of 
patients with AFD. Moreover, we are able to overcome 
the drawback of earlier studies on pulmonary function in 
patients with AFD5 because we now used z-scores, which 
are not biased by age, rather than the fixed cut-off ratio 
of FEV1/FVC <70%. The latter value generally leads to an 
underestimation of the prevalence of airflow limitation 
in younger individuals.23 25
There are some limitations of our study that have to 
be mentioned. First, the retrospective study design is a 
possible source of bias. However, a prospective inves-
tigation of the optimal time of ERT initiation is likely 
impossible due to ethical concerns. On the other hand, 
we did not compare treated and untreated patients since 
the latter group include mainly asymptomatic women. 
Second, Lyso-Gb3 values are subject to changes during 
ERT,17 45 which might have an effect on its applicability. 
The association of lysoGb3 and airflow limitation would 
possibly become significant, when only pre-ERT values 
were used for statistical analysis. A further limitation is 
that the number of Later-Onset patients is low in our 
cohort; therefore, our results need to be confirmed by 
studies with more Later-Onset patients. Lastly, since we 
normally do not perform body plethysmographies in 
Fabry patients, and since respiratory symptoms such as 
chronic cough and sputum production were not system-
atically captured, a clear differentiation from COPD is 
not possible, thus an overlap between Fabry-associated 
lung disease and COPD cannot not be excluded.
conclusIon
This is the first study to show a probable association in 
patients with AFD between plasma Lyso-Gb3 and airflow 
limitation on one hand, and an independent association 
between age at ERT initiation and FEV1 decline on the 
other hand. Thus, plasma Lyso-Gb3 could be useful as 
clinical predictor of pulmonary involvement by AFD, 
alongside conventional risk factors such as cigarette 
smoking, male gender and age. Furthermore, our data 
suggest earlier ERT initiation since this may help to stabi-
lise FEV1 decline and preserve pulmonary function. In 
addition, this is the first study demonstrating a signif-
icantly improved annual decline of FEV1/FVC z-score 
after initiation of ERT. Further studies are needed to 
confirm these findings.
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